5300 MEMORIAL DRIVE, HOUSTON, TX
Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control
Investor Presentation
Reg. FD
Presents ASCO 2026 Data Demonstrating No Detectable Cardiotoxicity with Annamycin Despite Exposure Levels Far Exceeding Conventional Anthracycline Limits
Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial
Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical Benchmarks
Q1
Amended Annual Report
FY 2025
Q3
Q2
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
PRE 14A
PRER14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload